Journal
LEUKEMIA
Volume 29, Issue 2, Pages 510-514Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2014.300
Keywords
-
Categories
Funding
- NCI NIH HHS [P01-CA078378, R01 CA050947, R01-CA050947, P01 CA078378, P01 CA155258, P50 CA100707] Funding Source: Medline
- PHS HHS [R01 178264, P01-155258, SPOREP50100707] Funding Source: Medline
Ask authors/readers for more resources
Heat shock protein 90 (HSP90) is a highly conserved molecular chaperone that interacts with various client proteins in eukaryotic cells:(1) Akt (PI3K/Akt pathway), interleukin-6 R (JAK/STAT pathway), Bcr-Abl (RAS/ERK pathway), Cyclin-dependent kinase 4, 6, 9 (cell cycling) and I kappa B kinases (NF-kappa B pathway).(2) The expression of HSP90 is upregulated (2- to 10-fold) in tumor cells compared with normal cells, reflecting multiple oncogenic pathways and maintenance of homeostasis within tumor cells.(1,2) Because HSP90 inhibition triggers downregulation /degradation of client proteins and triggers apoptosis, it is considered a promising target for novel targeted therapies. Indeed HSP90 inhibitors (for example, geldanamycin analog 17-allylamino-17-demethoxy-geldanamycin (17-AAG), resorcinol derivatives, purine analogs) have shown early promising results in vitro and in vivo in solid tumors and some hematological malignancies, including multiple myeloma (MM).(3,4) However, some clinical studies have been discontinued due to adverse effects, including ocular toxicity.(3,5) Therefore, development of a next-generation less-toxic HSP90 inhibitor remains an important therapeutic goal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available